Fewer than one in 10 patients eligible to benefit from obesity jabs including Wegovy can access them, caution the global health agency as it publishes its inaugural guidance on the drugs.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that excess weight is a long-term condition that can be managed with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key barriers to widespread access to the treatments that can help people shift considerable body mass, notes the organization.
Skinny Jab Shortage
Even under the present most optimistic case, the supply of such drugs could only cover approximately 100 million people – under 10% of those who need them, per the WHO.
The advice encourages governments and firms to widen access, via approaches such as voluntary licensing.
Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Drugs Function
These medications mimick a natural hormone to reduce digestion speed, reduce hunger and boost the sense of being full so people reduce food intake.
Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Research points to people may see weight return after a year of stopping the treatment, when their usual hunger resume.
Being overweight or obese raises your likelihood for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity impacts people in all nations and was linked to over three and a half million deaths worldwide in 2024, per the WHO.
